[混合生物人工肝支持系统治疗慢性肝衰竭急性发作患者的临床研究]
[Clinical study on hybrid bioartificial liver supporting system for acute on chronic liver failure patients].
作者信息
You Shao-Li, Liu Hong-Ling, Rong Yi-Hui, Zhu Bing, Liu Wan-Shu, Mao Pan-Yong, Xin Shao-Jie
机构信息
Liver Failure Therapeutic and Research Center, 302 Hospital of PLA, Beijing 100039, China.
出版信息
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Oct;25(5):387-9.
OBJECTIVE
To construct an hybrid bioartificial liver supporting system, and observe its effectiveness and safety on patients with acute on chronic liver failure.
METHODS
Hybrid bioartificial liver supporting system (HBALSS) was constructed using bioreactor with HepG2 cells transfected with human augmenter of liver regeneration (hALR) gene. 12 acute on chronic liver failure patients were divided into 2 groups randomly. The treatment group was treated with the hybrid bioartificial liver support system. The group underwent plasma exchange was used as control.
RESULTS
In the treatment group, four patients recovered, one patient died of hepatic encephalopathy, one patient died of hepatorenal syndrome, one patient recovered, but died of gastrointestnal bleeding after 1 year. In control group, two patients recovered, one patient underwent orthotropic liver transplantation, and three patients died of liver failure.
CONCLUSION
The hybrid bioartificial liver supporting system with HepG2 cell line was established successfully and have certain safety and effectiveness on acute on chronic liver failure patients.
目的
构建一种混合生物人工肝支持系统，并观察其对慢性肝衰竭急性发作患者的有效性和安全性。
方法
利用转染人肝再生增强因子（hALR）基因的HepG2细胞的生物反应器构建混合生物人工肝支持系统（HBALSS）。将12例慢性肝衰竭急性发作患者随机分为2组。治疗组采用混合生物人工肝支持系统进行治疗。以接受血浆置换的组作为对照。
结果
治疗组中，4例患者康复，1例患者死于肝性脑病，1例患者死于肝肾综合征，1例患者康复，但1年后死于胃肠道出血。对照组中，2例患者康复，1例患者接受了原位肝移植，3例患者死于肝衰竭。
结论
成功建立了带有HepG2细胞系的混合生物人工肝支持系统，对慢性肝衰竭急性发作患者具有一定的安全性和有效性。
Zotero 插件